Analysis Of Alternative Splicing Events Research Articles

Recurrent Oncogenic Mutations in CCND3 in Aggressive Lymphomas

Abstract 435The recent development of high throughput mRNA sequencing technologies has allowed major advances in the characterization and quantification of transcriptomes in human cancer. These advances include gene mutation detection, gene fusion discovery, analysis of alternative splicing events, and unbiased gene expression profiling.To comprehensively discover pathogenic sequence variants in lymphomas, we used Illumina technology to sequence mRNA of 206 lymphoma biopsies and cell lines, including 64 diffuse large B-cell lymphomas (DLBCL) of the activated B-cell-like (ABC) subtype, 71 DLBCL of the germinal center (GCB) subtype, and 41 Burkitt's lymphomas (BL). This effort uncovered a large number of mutations that were verified by Sanger sequencing.Using this methodology, we discovered somatic mutations in CCND3, encoding Cyclin D3, in 38 % of BLs, 14 % of ABC DLBCLs, and 10 % of GCB DLBCLs. These mutations stabilized the Cyclin D3 protein by altering a phosphorylation motif at Thr283 that is required for proteasomal degradation. Knockdown of CCND3 by RNA interference confirmed the oncogenic addiction to this gene in the mutated cell lines. In parallel, an RNA interference screen revealed that the cell lines that are dependent on CCND3 are also reliant on cyclin-dependent kinase 6 (CDK6), which together with Cyclin D3 regulates the G1/S transition of the cell cycle. Ectopic expression of the mutant CCND3 isoforms accelerated lymphoma cell line proliferation thereby demonstrating the oncogenic potential of these mutations.Remarkably, treatment of the CCND3/CDK6 addicted cell lines with a small molecule inhibitor of CDK 4/6 caused G1 arrest followed by apoptosis suggesting novel therapeutic strategies for these aggressive lymphomas. Disclosures:No relevant conflicts of interest to declare.

Whole genome exon arrays identify differential expression of alternatively spliced, cancer-related genes in lung cancer

Alternative processing of pre-mRNA transcripts is a major source of protein diversity in eukaryotes and has been implicated in several disease processes including cancer. In this study we have performed a genome wide analysis of alternative splicing events in lung adenocarcinoma. We found that 2369 of the 17 800 core Refseq genes appear to have alternative transcripts that are differentially expressed in lung adenocarcinoma versus normal. According to their known functions the largest subset of these genes (30.8%) is believed to be cancer related. Detailed analysis was performed for several genes using PCR, quantitative RT-PCR and DNA sequencing. We found overexpression of ERG variant 2 but not variant 1 in lung tumors and overexpression of CEACAM1 variant 1 but not variant 2 in lung tumors but not in breast or colon tumors. We also identified a novel, overexpressed variant of CDH3 and verified the existence and overexpression of a novel variant of P16 transcribed from the CDKN2A locus. These findings demonstrate how analysis of alternative pre-mRNA processing can shed additional light on differences between tumors and normal tissues as well as between different tumor types. Such studies may lead to the development of additional tools for tumor diagnosis, prognosis and therapy.

Integrating expression data with domain interaction networks

Summary: Recent studies have revealed that alternative splicing plays an important role in the observed protein and interaction diversity. Special microarrays allow for measuring gene expression at the exon level and thus for studying alternative transcripts and their corresponding protein domain architecture. We have developed the Cytoscape plugin DomainGraph that enables the visualization and detailed study of domain–domain interactions forming protein interaction networks. In addition, the integration of exon expression data supports the analysis of alternative splicing events and the characterization of their effects on the protein and domain interaction network. Different expression patterns between human tissues or cells can be identified by comparing the generated domain graphs.Availability: The plugin DomainGraph and the online documentation are available at http://domaingraph.bioinf.mpi-inf.mpg.de.Contact: mario.albrecht@mpi-inf.mpg.de

Promoter-sharing by different genes in human genome – CPNE1 and RBM12 gene pair as an example

BackgroundRegulation of gene expression plays important role in cellular functions. Co-regulation of different genes may indicate functional connection or even physical interaction between gene products. Thus analysis on genomic structures that may affect gene expression regulation could shed light on the functions of genes.ResultsIn a whole genome analysis of alternative splicing events, we found that two distinct genes, copine I (CPNE1) and RNA binding motif protein 12 (RBM12), share the most 5' exons and therefore the promoter region in human. Further analysis identified many gene pairs in human genome that share the same promoters and 5' exons but have totally different coding sequences. Analysis of genomic and expressed sequences, either cDNAs or expressed sequence tags (ESTs) for CPNE1 and RBM12, confirmed the conservation of this phenomenon during evolutionary courses. The co-expression of the two genes initiated from the same promoter is confirmed by Reverse Transcription-Polymerase Chain Reaction (RT-PCR) in different tissues in both human and mouse. High degrees of sequence conservation among multiple species in the 5'UTR region common to CPNE1 and RBM12 were also identified.ConclusionPromoter and 5'UTR sharing between CPNE1 and RBM12 is observed in human, mouse and zebrafish. Conservation of this genomic structure in evolutionary courses indicates potential functional interaction between the two genes. More than 20 other gene pairs in human genome were found to have the similar genomic structure in a genome-wide analysis, and it may represent a unique pattern of genomic arrangement that may affect expression regulation of the corresponding genes.

ProSAS: a database for analyzing alternative splicing in the context of protein structures

Alternative splicing is known to be one of the major sources for functional diversity in higher eukaryotes. Several splicing isoforms have been characterized in the literature that play important roles in cellular processes like apoptosis or signal transduction pathways. Splicing events can often be detected on the mRNA level by large-scale cDNA or EST experiments and such data is collected and annotated in several databases. Nevertheless, the effects of splicing on the structure of a protein are largely unknown. The ProSAS (Protein Structure and Alternative Splicing) database fills this gap and provides a unified resource for analyzing effects of alternative splicing events in the context of protein structures. ProSAS comprehensively annotates and models protein structures for several Ensembl genomes as well as SwissProt entries harbouring splicing events. Alternative isoforms annotated in Ensembl or SwissProt can be analyzed on the protein structure and protein function level using an intuitive user interface that provides several features and tools for a structure-based analysis of alternative splicing events. The ProSAS database is freely accessible at http://www.bio.ifi.lmu.de/ProSAS.

ASTALAVISTA: dynamic and flexible analysis of alternative splicing events in custom gene datasets

In the process of establishing more and more complete annotations of eukaryotic genomes, a constantly growing number of alternative splicing (AS) events has been reported over the last decade. Consequently, the increasing transcript coverage also revealed the real complexity of some variations in the exon–intron structure between transcript variants and the need for computational tools to address ‘complex’ AS events. ASTALAVISTA (alternative splicing transcriptional landscape visualization tool) employs an intuitive and complete notation system to univocally identify such events. The method extracts AS events dynamically from custom gene annotations, classifies them into groups of common types and visualizes a comprehensive picture of the resulting AS landscape. Thus, ASTALAVISTA can characterize AS for whole transcriptome data from reference annotations (GENCODE, REFSEQ, ENSEMBL) as well as for genes selected by the user according to common functional/structural attributes of interest: http://genome.imim.es/astalavista

Identification and analysis of alternative splicing events conserved in human and mouse.

Alternative pre-mRNA splicing affects a majority of human genes and plays important roles in development and disease. Alternative splicing (AS) events conserved since the divergence of human and mouse are likely of primary biological importance, but relatively few of such events are known. Here we describe sequence features that distinguish exons subject to evolutionarily conserved AS, which we call alternative conserved exons (ACEs), from other orthologous human/mouse exons and integrate these features into an exon classification algorithm, acescan. Genome-wide analysis of annotated orthologous human-mouse exon pairs identified approximately 2,000 predicted ACEs. Alternative splicing was verified in both human and mouse tissues by using an RT-PCR-sequencing protocol for 21 of 30 (70%) predicted ACEs tested, supporting the validity of a majority of acescan predictions. By contrast, AS was observed in mouse tissues for only 2 of 15 (13%) tested exons that had EST or cDNA evidence of AS in human but were not predicted ACEs, and AS was never observed for 11 negative control exons in human or mouse tissues. Predicted ACEs were much more likely to preserve the reading frame and less likely to disrupt protein domains than other AS events and were enriched in genes expressed in the brain and in genes involved in transcriptional regulation, RNA processing, and development. Our results also imply that the vast majority of AS events represented in the human EST database are not conserved in mouse.